Paul Kassner
Company: RAPT Therapeutics
Job title: Senior Vice President of Quantitative and Computational Biology
Seminars:
Chair’s Closing Remarks 5:15 pm
day: Day One
The CCR4 Antagonist, FLX475, Alters Treg Infiltration & Localization in the Tumor Microenvironment & Improves Clinical Response 4:15 pm
• Discovering how FLX475 works and its impact on altering Treg infiltration within the tumor microenvironment • Exploring how FLX475 influences Treg migration and localization, with a focus on strategies to target the tumor microenvironment for improved therapeutic outcomes • Uncovering the latest clinical trial results and future directions for utilizing FLX475 to enhance clinical…Read more
day: Day One